Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

No Link Found Between PCB Exposure and Cancer Mortality

May 1, 1999
Publication
Article
OncologyONCOLOGY Vol 13 No 5
Volume 13
Issue 5

In the largest human study of its kind, researchers Renate D. Kimbrough, MD, and Martha L. Doemland,PhD, have found

In the largest human study of its kind, researchers Renate D. Kimbrough, MD, and Martha L. Doemland,PhD, have found no association between actual human exposure to polychlorinated biphenyls (PCBs) and death from cancer or any other diseases.

For more than 20 years, the federal government has characterized PCBs as probable human carcinogens based, in part, on Dr. Kimbrough’s 1975 study of PCBs in rats fed a diet containing large quantities of the substance. “This new study provides strong evidence that even long-term human exposure to PCBs at higher levels than are found in the environment is not related to an increase in deaths from cancer or any other diseases,” said Dr. Kimbrough, the study’s principal investigator and a senior medical associate with the Institute for Evaluating Health Risks (IEHR) in Washington, DC.

The findings of the study, published in the March 1999 issue of the Journal of Occupational and Environmental Medicine, are consistent with those of four other studies of the same population conducted by other researchers over a span of nearly 25 years. However, the current study is the largest and most statistically powerful one to date.

Study Data

The study focused on 7,075 men and women who worked between 1946 and 1977 in two upstate New York General Electric factories that used PCBs in manufacturing electrical capacitors. The study compared the number (1,195) and causes of death within the study population to national and regional averages. The average follow-up time for study members was 31 years, providing a sufficiently long latency period in which to determine whether there was any increase in cancer mortality.

Some of the workers in the study had PCB levels in their blood as high as several thousand parts per billion—well above the average PCB levels found in the blood of people in the United States who have been tested (average PCB levels range from four to eight parts per billion, according to the Agency for Toxic Substances and Disease Registry).

Dr. John A. Moore, president of IEHR, said: “The findings of this study are consistent with a belief that cancer risks from exposure to PCBs have been overstated. The newer laboratory data of the past several years support such a view and also prompted the EPA to reduce the factors they use to estimate PCB cancer risks.”

Smaller Trials Confirm Validity of Current Findings

Dr. Arthur C. Upton, former director of the National Cancer Institute and currently a professor at the Robert Wood Johnson Medical School, said of the study: “This is a significant study that should be factored into any public discussion of PCBs and human health. Dr. Kimbrough and her colleagues were meticulous in their efforts to gather and verify information on the 7,075 individuals who were part of the investigation. The analysis of the data and conclusions are scientifically appropriate and the authors are to be complemented on the high quality of their study and report as well as the publication that was prepared from this information.”

Dr. Upton chaired a five-member advisory committee established by the IEHR to review the design, execution, analysis, and interpretation of the study.

“This was a well-designed and carefully conducted study,” said Dr. Jack Mandel, an epidemiologist and professor and director of environmental and occupational health at the University of Minnesota.

The study’s findings are consistent with shorter-term studies of workers in the same factories conducted by the National Institute for Occupational Safety and Health, Harvard School of Public Health, the New York State Department of Health, and the Mt. Sinai School of Medicine.

The IEHR conducted the study at the request of and with funding from General Electric, which operates the businesses where the workers were employed. General Electric had no role in the conduct of the study, the evaluation of the data, or the conclusions drawn, said Dr. Kimbrough.

Articles in this issue

Thalidomide Shows Promising Results in Patients With Multiple Myeloma
Bill Would Allow Medicaid to Pay for Cervical/Breast Cancer Treatment
Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer
Increased NIH Funding Needed to Combat Cancer in Minorities, Medically Underserved
Zeneca Launches Education Program Aimed at Reducing Breast Cancer Risk
Reinventing Bone Marrow Transplantation
Age Should Not Determine Treatment of SCLC Patients
Single Chest X-Ray Leads to Improved Lung Cancer Prognosis
No Link Found Between PCB Exposure and Cancer Mortality
Arsenic Induces Remissions in Patients With Acute Promyelocytic Leukemia
Cancer Outreach Programs for African-Americans
A 38-Year-Old Man With Pancreatic Cancer
ELVIS Study Results Offer Hope to Elderly Lung Cancer Patients
ASCO President Presses Medicare to Cover Costs of Cancer Clinical Trial Participants
Future Target for HIV Therapy: T-Cell’s Own Proteins

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.


The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Related Content

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.


Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.


Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.


The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.